

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/511,832
Filing Date	1/3/2006
First Named Inventor	Susan M. Freier
Art Unit	1635
Examiner Name	Sean McGarry
Attorney Docket Number	RTS-0428USA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A4	BJORNTORP et al., "Obesity and Cortisol" Nutrition (2000) 16:924-936.	
	A5	BRANCH et al., "A good antisense molecule is hard to find," TIBS (1998) 23:45-50.	
	A6	CHIN "On the Preparation and Utilization of Isolated and Purified Oligonucleotides" Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on March 14, 2002.	
	A7	CROOKE et al., "Basic Principles of Antisense Therapeutics" Antisense Research and Application (1998) Chapter 1:1-50.	
	A8	New England Biolabs 1998/99 Catalog (cover page and pages 121 and 284).	
	A9	REYNOLDS et al., "Rational siRNA design for RNA interference" Nature Biotechnology (2004) 22(3):326-330.	
	A10	SANGHVI et al., "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides" Antisense Research and Applications (1993) pages 273-288.	
	A11	SECKL et al., "Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action" Endocrinology (2001) 142:1371-1376.	
	A12	SHIMOJO et al., "Apparent mineralocorticoid excess syndromes" J. Endocrinol. Invest. (1995) 18:518-532.	
	A13	TANNIN et al., "The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization" J. Biol. Chem. (1991) 266:16653-16658.	
	A14	International Search Report for application PCT/US03/12544 dated 04/12/2003 (Atty. Docket no. RTS-0428WO).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.